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Stem cell technology is an exciting treatment in medicine
wherein ophthalmology is leading the way. The visibility
of the eye with our anatomic and histopathologic knowledge
allows for ease of assessment of stem cell treatments com-
pared to other neurological and visceral organs of the hu-
man body. Most of the ophthalmic stem cell headlines
come from treatment for posterior segment conditions, but
there is still much to learn about the complexities of retinal
cell differentiation, their safety, and the proper integration
of these cells into the highly complex neuro-retinal circuitry
(Lamba et al., 2009). Anterior segment stem cell technology,
due to its already well-deﬁned corneal limbal stem cells with
greater ease of evaluation, has been at the forefront of oph-
thalmic stem cell treatment and technology since 1997 (Pel-
legrini et al., 1997). This paper provides an overview of the
current standard of care for treatment of limbal stem-cell
deﬁcient conditions and reviews recent treatment technolo-
gies using ex vivo expansion of cultivated limbal stem cells
of the cornea.
1.1. Corneal limbal stem cell deﬁciency
Corneal epithelial cells are self-renewing: the squamous epithe-
lial cells renew themselves every seven days. The corneal limbal
stem cells (LSC) are made up of non-keratinizing stratiﬁed
squamous epithelium located at the basal layer of the epithe-
lium in the transition zone between corneal and conjunctival
epithelial cells. LSC prevent the conjunctival epithelium from
invading upon the corneal epithelium. They are also thought
to provide the source for corneal epithelial renewal (Tuli
et al., 2005).
Clinical symptoms of LSC deﬁciency include decreased vi-
sion, photophobia, tearing, blepharospasm, chronic inﬂamma-
tion and hyperemia, and recurrent episodes of pain (Dua and
Azuara-Blanco, 2000). Slit-lamp examination shows recurrent
and persistent epithelial defects, scarring, calciﬁcation, con-
junctivalization of the cornea, superﬁcial neovascularization
of the cornea, decreased mucin and aqueous tear production,
keratinization of the entire ocular surface, ulceration, melting,
and perforation (Dua and Azuara-Blanco, 2000).
LSC deﬁciency can occur from many causes and severity
can range from mild, as seen in contact lens overwear, to se-
vere, as in chemical burns and ocular cicatricial pemphigoid
(OCP). Causes of LSC deﬁciency include: aniridia, ectoder-
mal dysplasia, toxicity from topical medications, chemical
or thermal injury, radiation, Stevens-Johnson Syndrome
(SJS), ocular cicatricial pemphigoid, cryotherapy, multiple
surgeries, contact lens wear, conjunctival intraepithelialneoplasia, and microbial keratitis (Dua and Azuara-Blanco,
2000).
1.2. The evolution of limbal stem cell transplantation
In 1965, Barraquer reported the ﬁrst stem cell autograft using
conjunctival-limbal-corneal epithelium harvested from the
healthy fellow eyes of patients with unilateral chemical burns
(Barraquer, 1965). Keratoepithelioplasty was reported by
Thoft in 1984 using corneal lenticules from whole globes
(Thoft, 1982). The ﬁrst, modern LSC transplant was reported
in 1989 by Kenyon and Tseng on patients with unilateral LSC
disease with ocular surface stabilization in 19 of 20 eyes (Ken-
yon and Tseng, 1989). Further reﬁnements to this technique
evolved to maximize the harvesting and transplantation of lar-
ger amounts of conjunctiva and LSC from the donor to the re-
cipient ocular surface (Holland and Schwartz, 1996; Croasdale
et al., 1999; Holland et al., 2002). In 1997, Pellegrini et al. were
the ﬁrst to report on the successful use of autologous cultivated
corneal epithelium for restoring the ocular surface in two pa-
tients with severe unilateral alkali burns (Pellegrini et al.,
1997). This has led to the most recent advances in LSC tech-
nology involving the ex vivo expansion of cultivated corneal
epithelial LSC for transplantation.
2. Current management of limbal stem cell disease
Partial LSC deﬁciency is deﬁned as LSC deﬁciency less than
one-half of the entire LSC population. Subtotal LSC deﬁ-
ciency is greater than one-half of the entire LSC population,
while total LSC deﬁciency is deﬁned as loss of the entire
LSC population.
Mild partial LSC deﬁciency, where the central visual axis is
not involved and there is good visual acuity, needs only obser-
vation. Conservative management such as lubrication and re-
moval of any potential inciting causes (i.e., contact lens
wear) should be addressed.
Partial LSC deﬁciency that is symptomatic with irritation,
reduction in vision, and signs of conjunctivalization of the cor-
nea, requires mechanical debridement of the conjunctival epi-
thelium from the corneal surface with frequent follow-up
(Dua et al., 1994). This allows the corneal epithelium to heal
into the debrided area.
In severe LSC deﬁcient states, there are various surgical
procedures to transplant LSC to form a new source of corneal
epithelium once the host’s irregular epithelium and surface
neovascularization have been debrided. In 1996, Holland et
al. developed a classiﬁcation system for the surgical manage-
ment of severe ocular surface disease based on the source of
tissue used; whether the source is an autograft or allograft;
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ative or a cadaveric donor (Holland and Schwartz, 1996). The
LSC transplant also requires carrier tissue as it is not possible
to transplant LSC alone, hence the need for conjunctival tissue
(conjunctival limbal graft), corneal tissue (keratolimbal graft),
or both as a carrier for LSC (Dua and Azuara-Blanco, 2000).
The following four sections describe each group within this
classiﬁcation system.
2.1. Conjunctival limbal autograft (CLAU)
In CLAU, limbal tissue with a conjunctival carrier is harvested
from the healthy contralateral eye and transplanted to the LSC
deﬁcient eye. Since this is an autograft, there is no need for sys-
temic immunosuppression: a tremendous advantage over allo-
graft transplantation. CLAU can only be used for cases of
unilateral LSC deﬁciency such as unilateral burns. Caution
must be exercised due to the risks to the healthy donor eye that
iatrogenically becomes LSC deﬁcient secondary to harvesting
of its LSC for transplantation (Jenkins et al., 1993). CLAU
can only be used when the contralateral donor eye has a
healthy ocular surface with no risk of future LSC deﬁciency
(e.g., asymmetric OCP or SJS, prior history of ocular surface
trauma).
Two trapezoid-shaped CLAUs are harvested, each approx-
imately 6 mm at the limbus, extending 5–8 mm posteriorly in
the bulbar conjunctiva, with anterior extension into the cornea
anterior to the palisades of Vogt. They are usually harvested
from the 12 and 6 o’clock meridians of the donor eye. Atten-
tion is directed toward the recipient eye. A 360 peritomy is
performed with excision of the bulbar conjunctiva that is
extended posteriorly in the superior and inferior quadrants
to allow for placement of the two trapezoidal CLAUs. Super-
ﬁcial keratectomy of the entire corneal surface ensues, debrid-
ing irregular epithelium and pannus. The CLAUs are secured
into position using 10-0 nylon interrupted sutures (Holland
et al., 2005; Biber et al., 2010).
2.2. Living-related conjunctival limbal allograft (LR-CLAL)
In LR-CLAL, healthy limbal tissue with a conjunctival carrier
is harvested from a living relative and transplanted to the pa-
tient. Surgically, the technique is similar to the CLAU, but two
separate surgeries are required. Compared to keratolimbal
allografts (KLAL), LR-CLAL transplants conjunctival tissue
that would be beneﬁcial for patients with compromised con-
junctiva. The advantage in using LR-CLAL over CLAU is
that it can be used in patients with bilateral LSC deﬁciency,
such as SJS and OCP (Daya et al., 2001; Kwitko et al.,
1995). However, unlike autografts, allografts are at risk for
rejection, and thus require both topical and systemic immuno-
suppression (Rao et al., 1999).
Surgeons should be conservative when selecting recipient
patients and donors. The recipient must be medically ﬁt to
withstand systemic, and most likely, lifelong immunosuppres-
sion. The patient must be compliant with medications and
postoperative appointments with the transplant surgeon and
transplant physicians. The patient must be able to comply with
the rigorous monitoring and bloodwork schedules postopera-
tively. Donors must be screened for potential risk of iatrogenic
LSC deﬁciency in the future. Only a limited amount of LSCcan be harvested from the donor, thus fewer LSC can be trans-
planted so patients with limited LSC deﬁciency are better sui-
ted for LR-CLAL compared to patients with complete LSC
deﬁciency (Holland et al., 2005; Biber et al., 2010).
2.3. Keratolimbal allograft (KLAL)
In KLAL, the recipient receives limbal tissue harvested from
cadaveric eyes using corneal tissue as a carrier. This allows for
a greater quantity of LSC transplanted to the recipient eye.
KLAL is ideal for severe bilateral LSC deﬁciency, patients with
unilateral LSC deﬁciency unwilling to risk LSC deﬁciency in
their better eye with a CLAU, or in patients who are unable to
obtain a willing and living relative for a LR-CLAL. Conditions
such as aniridia and iatrogenic LSCdeﬁciencywithmild tomod-
erate conjunctival involvement (Schwartz and Holland, 1998)
are ideal for KLAL. However, KLAL alone should not be used
in recipients with inadequate tear ﬁlm (Shimazaki et al., 2000),
signiﬁcant active inﬂammation, and/or severe conjunctival
involvement with keratinization of the ocular surface secondary
to loss of both LSC and conjunctival epithelial stem cells (Tsu-
bota and Shimazaki, 1999). As mentioned previously, systemic
immunosuppression is required with any allograft. The surgical
technique for this procedure has been described in detail (Hol-
land et al., 2005; Biber et al., 2010; Lim et al., 2008).
2.4. Combined conjunctival and keratolimbal limbal allograft
(C-KLAL)
In C-KLAL, the recipient receives transplantation of KLAL as
well as LR-CLAL. This is the preferred procedure in cases
with cicatrizing ocular surface disease, such as SJS, OCP,
and severe chemical burns. The conjunctival transplantation
provides additional functional goblet cells to improve the pro-
duction of mucin in the tear layer. These patients require
reconstruction of the conjunctival fornices and lids. Collabora-
tion with an oculoplastics surgeon and possibly an otolaryn-
gologist (for harvesting of nasal mucosa from the inferior
turbinates) is required (Holland et al., 2005; Biber et al.,
2010). Systemic immunosuppression is required.
3. Stem cell technology and corneal epithelial therapy
There are three types of stem cell lines: human embryonic stem
cells (hESC), induced pluripotent stem cells (iPSC), and tissue-
stem cells. The original stem cells, the hESC, come from hu-
man blastocysts and are pluripotent; however, these cells carry
tumorigenesis and immunologic rejection issues. The iPSC are
further differentiated from the hESC; however, cultivation of
these cells has shown low yield with inconsistent tissue lines.
Tissue-stem cells are further differentiated stem cells and are
unipotent, progenitor cells with minimal tumorigenicity and
immunologic reaction.
The corneal LSC are an example of tissue-stem cells that have
been successfully identiﬁed and used to repair ocular surface dis-
ease. The LSC provide the source for corneal epithelial renewal.
They are made up of non-keratinizing stratiﬁed squamous epi-
thelium located at the basal layer of the epithelium in the transi-
tion zone between corneal and conjunctival epithelial cells––the
LSC niche. Confocal microscopy has shown how injury to the
limbus has affected the LSC niche (Shortt et al., 2007a).
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Penetrating keratoplasty has a poor prognosis in patients with
severe LSC deﬁciency. LSC transplantation can optimize the
success rate; however, there are associated risks of inducing
LSC deﬁciency in the donor eye, as well as the need for sys-
temic immunosuppression if the donor is an allograft––either
from a living related or cadaveric donor.
In 1997, Pellegrini et al. were the ﬁrst to successfully treat
two patients with total LSC deﬁciency by cultivating autolo-
gous corneal epithelium (Pellegrini et al., 1997). A 1 mm2
LSC donor biopsy was taken from the patients’ healthy con-
tralateral eye. The biopsy was then minced, treated with tryp-
sin, and the LSC were isolated and expanded on culture plastic
using lethally irradiated mouse 3t3 ﬁbroblast feeder cells. The
cultivated epithelial progenitor cells were then successfully
transplanted to the recipient eye using a soft contact lens as
a carrier. With follow-up of greater than two years, both
patients had achieved re-epithelialization of the entire cornea.
This landmark study introduced a new perspective in the
treatment of LSC deﬁciency by reducing the risk of morbidity
in the donor and maintaining an autologous source.
In cases of bilateral LSC deﬁciency such as aniridia and
SJS, an allogeneic LSC donor source, either living-related or
cadaveric, is required. Reports are supportive of using
ex vivo expanded LSC allograft, but long-term success has
yet to be established (Shortt et al., 2007b; Daya et al., 2005).
3.2. Amniotic membrane and other carrier substrates
Human amniotic membrane, the inner wall of the membra-
nous sac surrounding the embryo during gestation, is the most
common carrier substrate used for LSC culture and transplan-
tation. Amniotic membrane provides the cultured LSC with a
surrogate niche to assist with survival and function. Amniotic
membrane has inherent anti-scarring, anti-angiogenic and
anti-inﬂammatory mediators that enhance re-epithelialization
of the ocular surface (Tseng et al., 1998; Schwab et al., 2000;
Shimazaki et al., 2002; Grueterich et al., 2002; Tsai et al.,
2004). The use of amniotic membrane simpliﬁes manipulation
and suturing, while reducing the risk of potential infection
associated with using the mouse 3t3 ﬁbroblast feeder cells.
Amniotic membrane also acts as a basement membrane en-
abling cell migration (Dua et al., 2004).
Amniotic membrane is a substrate that allows the LSC to
survive and proliferate; however, it requires costly donor
screening and there is a potential for transmission of viral
disease. Amniotic membrane is also expensive, not readily
available, and semi-opaque which may affect vision postoper-
atively. Processing methods of amniotic membrane are vari-
able and may affect the ability of the amnion to act as a
suitable substrate for LSC cultivation. The use of glycerol as
a cryoprotectant when processing amniotic membrane has
been shown to impair LSC expansion when compared to
simple frozen amniotic membrane (Shortt et al., 2009).
Various alternative substrates have been used for corneal
epithelial transplantation. These include: ﬁbrin substrate with
good results at up to 10 years of follow-up (Rama et al.,
2001, 2010); a novel cell-sheet manipulation technology using
temperature-responsive culture dishes (Nishida et al., 2004);
acrylic acid plasma polymerization to coat the inner surfaceof a bandage contact lens used to cultivate, transport, and
immobilize the tissue (Notara et al., 2007); carrier-free sheets
using commercially available ﬁbrin sealant (Higa and Shima-
zaki, 2008); and autologous serum incorporated into growth
media with an FDA-approved soft contact lens as the sub-
strate, carrier, and bandage to protect the eye during trans-
plantation and healing (Di Girolamo et al., 2009).3.3. Alternate sources of corneal epithelial cells for
transplantation
Autologous LSC transplantation and ex vivo expansion of cul-
tured autologous corneal epithelial LSC do not require sys-
temic immunosuppression. However, in cases of bilateral,
total LSC deﬁciency where autologous corneal epithelial
LSC tissue is not available for harvesting and expansion,
living-related or cadaveric donor allograft with long-term
systemic immunosuppression are required. Immunosuppres-
sion carries a high risk of serious ocular and systemic
complications.
Alternate sources of autologous epithelial cells have been
studied in order to avoid the need for systemic immunosup-
pression in patients with severe bilateral LSC deﬁciency. Oral
mucosal epithelial cells (Notara et al., 2010; Nakamura
et al., 2004; Nishida et al., 2004; Inatomi et al., 2006), mesen-
chymal stem cells (Ye et al., 2006; De Miguel et al., 2010; Joe
and Gregory-Evans, 2010), and hair follicle stem cells (Blaz-
ejewska et al., 2009) may be possible alternative sources.
The in vitro replication of pluripotent hESC derived from
blastocysts has been successfully achieved (Ahmad et al.,
2007); however, the translation to human therapeutic use must
overcome problems with functionality, rejection, and ethical
concerns. iPSC have been generated (Takahashi et al., 2007;
Park et al., 2008), but challenges still exist with tumorigenicity,
immune rejection, reﬁning a speciﬁc population, and deﬁning
an appropriate model for preclinical studies. The translation
of hESC and iPSC technology to human therapeutics is an
exciting ﬁeld that will continue to evolve and develop in future.
3.4. Challenges in using corneal limbal stem cell technology and
therapy
There are many challenges in LSC technology and therapy.
Most methods of ex vivo LSC expansion require the use of ani-
mal products, foreign human tissue/serum, and/or non-ap-
proved biomaterials, all increasing the potential risk of
xenobiotic infection. Ethical considerations are at the forefront
in using hESC as they are harvested directly from blastocysts
generated through in vitro fertilization. hESC and iPSC still
have complexities with tumorigenicity, immune rejection,
reﬁnement to a speciﬁc population, and deﬁning appropriate
models for preclinical studies.
It is difﬁcult to interpret and compare the efﬁcacy of the
numerous ex vivo expansion studies published because of var-
iation among the studies. The main variables are: culture tech-
niques employed, selection of recipient patients for treatment
(degree of LSC deﬁciency in the recipients), evaluation of
treatment efﬁcacy (clinical observation vs. impression cytol-
ogy), lack of outcomes data (visual acuity not reported in some
series), variation in follow-up, and the combined use of autol-
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2007b; Ahmad et al., 2010). Despite these challenges, the re-
sults are favorable. A recent review summarized the results
of 15 studies utilizing autografts showing an 84% success rate
in 292 transplants: in nine studies with allografts, there was a
75% success rate in 48 transplants (Ahmad et al., 2010). Fur-
ther studies with standardized variables will allow for easier
interpretation of technology and therapeutic outcomes.4. Conclusions
Penetrating keratoplasty has a poor prognosis in patients with
severe LSC deﬁciency. LSC transplantation optimizes the suc-
cess rate; however, there are associated risks of inducing LSC
deﬁciency in the donor eye, as well as the need for systemic
immunosuppression if the donor is an allograft––either from
a living related or cadaveric donor. The clinical use of ex vivo
expansion of cultivated autologous LSC was ﬁrst described in
1997 (Pellegrini et al., 1997). Modiﬁcation of this technique
and expansion using amniotic membrane and other carrier sub-
strates has enhanced the translation to clinical therapy.
The recent landmark phase 1 clinical study using tissue
engineering to produce a biosynthetic cornea has garnered
much media interest toward penetrating keratoplasty technol-
ogy (Fagerholm et al., 2010). A biosynthetic cornea minimizes
the risk of rejection, but still requires healthy endothelium and
LSC in the recipient, thus highlighting the importance of LSC
technology. As LSC technology and tissue engineering con-
tinue to evolve, ophthalmologists will have alternatives to
manage severe, bilateral LSC deﬁcient conditions, such as
chemical burns, SJS, and OCP without the need for systemic
immunosuppression and donated cadaveric tissue.
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